消化

订阅

MedSci主页 / 所有栏目 / 消化

Applied Therapeutics宣布启动AT-007在半乳糖血症中的I/II期研究

2019-06-25 Allan MedSci原创

AT-007半乳糖血症GALK缺陷
关注

Applied Therapeutics是一家临床阶段的生物制药公司，近日宣布，将启动AT-007在半乳糖血症中的I/II期研究。这项名为ACTION-Galactosemia的试验将研究AT-007的安全性和药代动力学。

Applied Therapeutics是一家临床阶段的生物制药公司，近日宣布，将启动AT-007在半乳糖血症中的I/II期研究。这项名为ACTION-Galactosemia的试验将研究AT-007的安全性和药代动力学。这项多中心研究将主要招募患有经典半乳糖血症的患者，这是美国最常见的半乳糖血症，但也将招募一组GALK缺陷（GALKD）患者，这是欧洲常见的半乳糖血症。

Applied Therapeutics的首席医疗官、医学博士Riccardo Perfetti说：“单独的饮食限制不会阻止疾病的长期并发症，因为患者身体会内源性地产生半乳糖，因此半乳糖血症患者迫切需要治疗方案。我们正致力于通过临床开发尽快推进AT-007”。


原始出处：

http://www.firstwordpharma.com/node/1649148#axzz5rpYDX3hI

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728032, encodeId=74881e280329c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084014, encodeId=68862084014fc, content=<a href='/topic/show?id=404c2912ce' target=_blank style='color:#2F92EE;'>#AT-007#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2912, encryptionId=404c2912ce, topicName=AT-007)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 25 21:21:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974373, encodeId=6a7519e43730d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Wed Aug 21 09:21:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738961, encodeId=ca731e3896126, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 10 22:21:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588739, encodeId=dfd21588e39ad, content=<a href='/topic/show?id=8ac523668e8' target=_blank style='color:#2F92EE;'>#乳糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23668, encryptionId=8ac523668e8, topicName=乳糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5a17619424, createdName=minzju5058, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2020-04-07 feather89

    #PE#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1728032, encodeId=74881e280329c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084014, encodeId=68862084014fc, content=<a href='/topic/show?id=404c2912ce' target=_blank style='color:#2F92EE;'>#AT-007#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2912, encryptionId=404c2912ce, topicName=AT-007)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 25 21:21:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974373, encodeId=6a7519e43730d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Wed Aug 21 09:21:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738961, encodeId=ca731e3896126, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 10 22:21:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588739, encodeId=dfd21588e39ad, content=<a href='/topic/show?id=8ac523668e8' target=_blank style='color:#2F92EE;'>#乳糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23668, encryptionId=8ac523668e8, topicName=乳糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5a17619424, createdName=minzju5058, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-10-25 般若傻瓜

    #AT-007#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1728032, encodeId=74881e280329c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084014, encodeId=68862084014fc, content=<a href='/topic/show?id=404c2912ce' target=_blank style='color:#2F92EE;'>#AT-007#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2912, encryptionId=404c2912ce, topicName=AT-007)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 25 21:21:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974373, encodeId=6a7519e43730d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Wed Aug 21 09:21:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738961, encodeId=ca731e3896126, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 10 22:21:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588739, encodeId=dfd21588e39ad, content=<a href='/topic/show?id=8ac523668e8' target=_blank style='color:#2F92EE;'>#乳糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23668, encryptionId=8ac523668e8, topicName=乳糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5a17619424, createdName=minzju5058, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-08-21 ms24272190615788285182

    #Therapeutic#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1728032, encodeId=74881e280329c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084014, encodeId=68862084014fc, content=<a href='/topic/show?id=404c2912ce' target=_blank style='color:#2F92EE;'>#AT-007#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2912, encryptionId=404c2912ce, topicName=AT-007)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 25 21:21:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974373, encodeId=6a7519e43730d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Wed Aug 21 09:21:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738961, encodeId=ca731e3896126, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 10 22:21:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588739, encodeId=dfd21588e39ad, content=<a href='/topic/show?id=8ac523668e8' target=_blank style='color:#2F92EE;'>#乳糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23668, encryptionId=8ac523668e8, topicName=乳糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5a17619424, createdName=minzju5058, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-12-10 124988c7m106暂无昵称

    #ERA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1728032, encodeId=74881e280329c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084014, encodeId=68862084014fc, content=<a href='/topic/show?id=404c2912ce' target=_blank style='color:#2F92EE;'>#AT-007#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2912, encryptionId=404c2912ce, topicName=AT-007)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 25 21:21:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974373, encodeId=6a7519e43730d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Wed Aug 21 09:21:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738961, encodeId=ca731e3896126, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 10 22:21:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588739, encodeId=dfd21588e39ad, content=<a href='/topic/show?id=8ac523668e8' target=_blank style='color:#2F92EE;'>#乳糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23668, encryptionId=8ac523668e8, topicName=乳糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5a17619424, createdName=minzju5058, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-06-27 zhaojie88

    #therapeutics#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1728032, encodeId=74881e280329c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Apr 07 06:21:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084014, encodeId=68862084014fc, content=<a href='/topic/show?id=404c2912ce' target=_blank style='color:#2F92EE;'>#AT-007#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2912, encryptionId=404c2912ce, topicName=AT-007)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Fri Oct 25 21:21:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974373, encodeId=6a7519e43730d, content=<a href='/topic/show?id=fdec1e3842b' target=_blank style='color:#2F92EE;'>#Therapeutic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17384, encryptionId=fdec1e3842b, topicName=Therapeutic)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Wed Aug 21 09:21:00 CST 2019, time=2019-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738961, encodeId=ca731e3896126, content=<a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6913, encryptionId=6e566913df, topicName=ERA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e36234488643, createdName=124988c7m106暂无昵称, createdTime=Tue Dec 10 22:21:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350824, encodeId=e3e51350824cc, content=<a href='/topic/show?id=a2fb1e385a1' target=_blank style='color:#2F92EE;'>#therapeutics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17385, encryptionId=a2fb1e385a1, topicName=therapeutics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588739, encodeId=dfd21588e39ad, content=<a href='/topic/show?id=8ac523668e8' target=_blank style='color:#2F92EE;'>#乳糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23668, encryptionId=8ac523668e8, topicName=乳糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5a17619424, createdName=minzju5058, createdTime=Thu Jun 27 07:21:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-06-27 minzju5058

    #乳糖#

    0